Clinical trial

M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)

NCT03840902

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2019-04-16

PhasePHASE2

Study timeline

Study start (actual)2019-04-16Date precision: day

Registry last updated2024-01-16

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Non-small Cell Lung Cancerunresolved

Interventions

DurvalumabDRUG · verified · RxNorm: durvalumab

EtoposideDRUG · verified · RxNorm: etoposide

PemetrexedDRUG · verified · RxNorm: pemetrexed

CarboplatinDRUG · verified · RxNorm: carboplatin

PaclitaxelDRUG · verified · RxNorm: paclitaxel

CisplatinDRUG · verified · RxNorm: cisplatin

Intensity Modulated Radiation Therapy (IMRT)RADIATION

Sponsors & collaborators

EMD Serono Research & Development Institute, Inc.lead sponsor

Merck KGaA, Darmstadt, Germanycollaborator

Mapped research locations

SeoulSouth Korea4 MadridSpain4 BarcelonaSpain3 SevilleSpain3 IndianapolisIndiana, United States2 TaipeiTaiwan2 ValenciaSpain2 São PauloBrazil2 Porto AlegreBrazil2 New YorkNew York, United States1 HoustonTexas, United States1 ChicagoIllinois, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03840902 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.